274 related articles for article (PubMed ID: 22452977)
1. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Tannheimer SL; Wright CD; Salmon M
Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
[TBL] [Abstract][Full Text] [Related]
2. A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro.
Sabatini F; Petecchia L; Boero S; Silvestri M; Klar J; Tenor H; Beume R; Hatzelmann A; Rossi GA
Pulm Pharmacol Ther; 2010 Aug; 23(4):283-91. PubMed ID: 20226872
[TBL] [Abstract][Full Text] [Related]
3. Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis.
Joshi R; Yan D; Hamed O; Mostafa MM; Joshi T; Newton R; Giembycz MA
Mol Pharmacol; 2019 Jul; 96(1):56-72. PubMed ID: 31036559
[TBL] [Abstract][Full Text] [Related]
4. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
Togo S; Liu X; Wang X; Sugiura H; Kamio K; Kawasaki S; Kobayashi T; Ertl RF; Ahn Y; Holz O; Magnussen H; Fredriksson K; Skold CM; Rennard SI
Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L959-69. PubMed ID: 19304913
[TBL] [Abstract][Full Text] [Related]
5. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Tannheimer SL; Sorensen EA; Haran AC; Mansfield CN; Wright CD; Salmon M
Pulm Pharmacol Ther; 2012 Apr; 25(2):178-84. PubMed ID: 22306235
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
7. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes.
Namba Y; Togo S; Tulafu M; Kadoya K; Nagahama KY; Taka H; Kaga N; Orimo A; Liu X; Takahashi K
Respir Res; 2017 Mar; 18(1):46. PubMed ID: 28284212
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast, indacaterol maleate, and abiraterone acetate.
Hussar DA; DePasquale J
J Am Pharm Assoc (2003); 2011; 51(5):668-71. PubMed ID: 21896467
[No Abstract] [Full Text] [Related]
9. Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Reddy AT; Lakshmi SP; Banno A; Reddy RC
Int J Chron Obstruct Pulmon Dis; 2020; 15():125-134. PubMed ID: 32021151
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.
Buenestado A; Chaumais MC; Grassin-Delyle S; Risse PA; Naline E; Longchampt E; Tenor H; Devillier P
PLoS One; 2013; 8(9):e74640. PubMed ID: 24066150
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of CX3CL1 Attenuates TGF-β-Induced Fibroblast Differentiation Through NF-κB Activation and Mitochondrial Dysfunction in Airway Fibrosis.
Cheng WH; Chang PL; Wu YC; Wang SA; Chen CL; Hsu FL; Neoh MM; Lin LY; Yuliani FS; Lin CH; Chen BC
Lung; 2024 Jun; 202(3):343-356. PubMed ID: 38678499
[TBL] [Abstract][Full Text] [Related]
12. The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist.
Tannheimer SL; Sorensen EA; Cui ZH; Kim M; Patel L; Baker WR; Phillips GB; Wright CD; Salmon M
J Pharmacol Exp Ther; 2014 Apr; 349(1):85-93. PubMed ID: 24513870
[TBL] [Abstract][Full Text] [Related]
13. Effect of roflumilast, novel phosphodiesterase-4 inhibitor, on lung chronic graft-versus-host disease in mice.
Kim SW; Lim JY; Rhee CK; Kim JH; Park CK; Kim TJ; Cho CS; Min CK; Yoon HK
Exp Hematol; 2016 May; 44(5):332-341.e4. PubMed ID: 26898707
[TBL] [Abstract][Full Text] [Related]
14. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
Lea S; Metryka A; Li J; Higham A; Bridgewood C; Villetti G; Civelli M; Facchinetti F; Singh D
Cytokine; 2019 Nov; 123():154739. PubMed ID: 31319374
[TBL] [Abstract][Full Text] [Related]
15. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro.
Burgess JK; Oliver BG; Poniris MH; Ge Q; Boustany S; Cox N; Moir LM; Johnson PR; Black JL
J Allergy Clin Immunol; 2006 Sep; 118(3):649-57. PubMed ID: 16950284
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of long-acting β
Kim Y; Hou V; Huff RD; Aguiar JA; Revill S; Tiessen N; Cao Q; Miller MS; Inman MD; Ask K; Doxey AC; Hirota JA
Respir Res; 2021 Oct; 22(1):266. PubMed ID: 34666750
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast N-Oxide in Combination with Formoterol Enhances the Antiinflammatory Effect of Dexamethasone in Airway Smooth Muscle Cells.
Patel BS; Rahman MM; Baehring G; Xenaki D; Tang FS; Oliver BG; Ammit AJ
Am J Respir Cell Mol Biol; 2017 Apr; 56(4):532-538. PubMed ID: 27997807
[TBL] [Abstract][Full Text] [Related]
18. CREB regulates TNF-α-induced GM-CSF secretion via p38 MAPK in human lung fibroblasts.
Koga Y; Hisada T; Ishizuka T; Utsugi M; Ono A; Yatomi M; Kamide Y; Aoki-Saito H; Tsurumaki H; Dobashi K; Yamada M
Allergol Int; 2016 Oct; 65(4):406-413. PubMed ID: 27118435
[TBL] [Abstract][Full Text] [Related]
19. Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Totani L; Amore C; Di Santo A; Dell'Elba G; Piccoli A; Martelli N; Tenor H; Beume R; Evangelista V
J Thromb Haemost; 2016 Jan; 14(1):191-204. PubMed ID: 26484898
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.
Buenestado A; Grassin-Delyle S; Guitard F; Naline E; Faisy C; Israël-Biet D; Sage E; Bellamy JF; Tenor H; Devillier P
Br J Pharmacol; 2012 Mar; 165(6):1877-1890. PubMed ID: 21913898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
